PRAGMA Therapeutics
Saint-julien-en-genevois
About PRAGMA Therapeutics
PRAGMA Therapeutics is a French leading neuroscience biotech company discovering and developing proprietary small molecule therapeutics for the treatment of stress-related diseases, in particular Post-Traumatic Stress Disorders (PTSD), and hearing loss. Founded in 2015, PRAGMA is a flexible organization led by a team with a world-leading experience in neuroscience drug development, targeting a specific class of G-protein-coupled receptors (GPCR), the metabotropic glutamate receptors family (mGluRs). PRAGMA currently develops allosteric modulators of the mGlu7 subtype which corresponds to a unique and innovative approach to regulate stress-related responses, fear and cognitive dysfunctions associated to PTSD, as well as acute and acoustic trauma-induced hearing loss. PRAGMA has integrated the new standards of drug development and aims at rapidly correlating in vivo proof-of-concept studies with target engagement and pharmacodynamic biomarkers in human in order to increase its success rate in clinical trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $1.7M
- Funding stage: Seed
- Last round: Seed (Nov 2018)
- Website: pragmatherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Neuroscience, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/pragma-therapeutics-30462 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.